| Ref ID | 1038 |
| First Author | M. Mainou |
| Journal | ANNALS OF HEMATOLOGY |
| Year Of Publishing | 2024 |
| URL | https://link.springer.com/article/10.1007/s00277-023-05517-7 |
| Keywords |
• Harms • Oncology • Low methodological quality • Disclosure • Protocols • Haematology |
| Problem(s) |
• No registered or published protocol • Low methodological (AMSTAR) quality • Conflicts of interest or funding of included studies not assessed • Reasons for excluding potentially eligible studies not provided • Meta-analyses and forest plots presented without considering risk of bias / quality |
| Article Type | Empirical |
| Article Subtype | Cross-sectional survey/Methodological systematic review |
| First Author Country | Greece |
| Checklists |
• AMSTAR 2 |
| Aim | To present all systematic reviews (SRs) indexed on Medline, Cochrane Library, Epistemonikos.org up to September 2023, focusing on adverse events due to antimyeloma treatments, the methods of identifying and presenting adverse events, and the use of appropriate methods to synthesize the results, as well as reproducibility of results. |
| Level of Investigation | Descriptive |
| Summary of Findings | From 23 included 7 SRs indexed on Medline, Cochrane Library, Epistemonikos.org up to September 2023, focusing on adverse events due to antimyeloma treatments. The quality of included studies as judged by AMSTAR 2 was mostly critically low. None of the reviews provided a list of excluded studies, or reported on the sources of funding of studies, only 1 review assessed the potential impact of risk of bias in individual studies on the results of the meta-analysis, and 9 reviews (39.1%) did not have an a priori registered protocol. |
| Number of systematic reviews included | 23 |
| Number of eligible systematic reviews assessed | 1966 |
| Treatment impacted | Not Applicable |
| Treatment impacted description | |
| Interpretation impacted | Not Applicable |
| Interpretation impacted description |